OverviewSuggest Edit

InnoCare is a biopharmaceutical company specializing in drug development for the treatment of cancer and autoimmune diseases. It produces Orelabrutinib, a selective and irreversible small-molecule BTK inhibitor for patients with B-cell malignancies. In addition, the company aims to develop drugs for treating autoimmune diseases induced by T-cell dysfunction.

Latest Updates

Employees (est.) (Sept 2021)68(+5%)
Cybersecurity ratingBMore

Key People/Management at InnoCare

Jasmine Cui Ph

Jasmine Cui Ph

Co-Founder President and CEO
Rick Xu Ph

Rick Xu Ph

Shaojing Tong

Shaojing Tong

Xiangyang Chen Ph

Xiangyang Chen Ph

Renbin Zhao Ph

Renbin Zhao Ph

Executive Director of Biology and Clinical Development Strategy
Norman Kong Ph

Norman Kong Ph

Executive Director of Medicinal Chemistry
Show more

InnoCare Office Locations

InnoCare has offices in Guangzhou Shi, Nanjing Shi, Cambridge and Princeton
Guangzhou Shi, CN
room 208, building b, 98 Xiangxue 8th Rd, Huangpu Qu
Nanjing Shi, CN
Long Mian Da Dao, Jiangning Qu
Cambridge, MA, US
1 Broadway
Princeton, NJ, US
103 Carnegie Center
Show all (6)

InnoCare Financials and Metrics

Summary Metrics

Founding Date


InnoCare total Funding

$215 m

InnoCare latest funding size

$160 m

Time since last funding

3 years ago

InnoCare investors

InnoCare's latest funding round in January 2019 was reported to be $160 m. In total, InnoCare has raised $215 m
Show all financial metrics

InnoCare Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

InnoCare Online and Social Media Presence

Embed Graph

InnoCare News and Updates

InnoCare Releases 2021 Half Year Results and Business Highlights

BEIJING, Aug. 29, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 half year results which ended on June 30, 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "On...

InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332

BEIJING, Aug. 15, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on drug innovation for cancer and autoimmune diseases, announced today the first subject dosed in clinical trial of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 in China....

InnoCare Frequently Asked Questions

  • When was InnoCare founded?

    InnoCare was founded in 2013.

  • Who are InnoCare key executives?

    InnoCare's key executives are Jasmine Cui Ph, Rick Xu Ph and Shaojing Tong.

  • How many employees does InnoCare have?

    InnoCare has 68 employees.

  • Who are InnoCare competitors?

    Competitors of InnoCare include SK Biopharmaceuticals, Spectrum Pharmaceuticals and HUYA Bioscience International.

  • Where are InnoCare offices?

    InnoCare has offices in Guangzhou Shi, Nanjing Shi, Cambridge and Princeton.

  • How many offices does InnoCare have?

    InnoCare has 6 offices.